Navigation Links
Watson to Host and Webcast Investment Community Meeting at American Urological Association Annual Meeting

- Company to Highlight Data for its Two Newest Urological Products -

CORONA, Calif., April 22 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a global leader in the development and distribution of pharmaceuticals, announced today that management will host and webcast a meeting for the investment community at the American Urological Association (AUA) Annual Meeting taking place in Chicago, Illinois, April 25-30, 2009.

The company will be hosting the meeting to review new data on its two newest brands, RAPAFLO (silodosin) and GELNIQUE (oxybutynin chloride) Gel 10%, including:

  • Two post-hoc analyses of Phase 3 trials for RAPAFLO(TM) (silodosin): On efficacy, specifically for irritative and obstructive symptoms; and retrograde ejaculation - a harmless side effect of treatment - as an indicator of treatment efficacy. Reviewed by Herbert Lepor, M.D., Department of Urology, New York University School of Medicine, NY
  • The efficacy, safety and tolerability of GELNIQUE(TM) (oxybutynin chloride) Gel 10% versus placebo from Phase 3 trials. Reviewed by Roger R. Dmochowski, M.D., Department of Urologic Surgery, Vanderbilt University School of Medicine, Nashville, TN

The event will be held on Monday, April 27, 2009, from 3:00 p.m. to 5:00 p.m. (CDT) at The Hyatt McCormick in Conference Center Room 12D, adjacent to the McCormick Center, where the AUA meeting is being held. To participate in the event in person, please RSVP to Scott Anderson, Watson Pharmaceuticals, by Friday, April 24, via e-mail,, or phone, (951) 493-9684.

The presentation will be webcast live and can be accessed on Watson Pharmaceuticals' Investor Relations Web site at Pre-registration is not required to view the webcast. An archived version will be available for 30 days after the live presentation and can be accessed at the same location.

About Watson Pharmaceuticals, Inc.

Watson Pharmaceuticals, Inc. is a global leader in the development and distribution of pharmaceuticals with a broad portfolio of generic products and a specialized portfolio of branded pharmaceuticals focused on Urology, Women's Health and Nephrology (Medical).

In the U.S., the Watson portfolio includes RAPAFLO, GELNIQUE, TRELSTAR(R) LA and TRELSTAR(R) Depot, Ferrlecit(R), INFeD(R), and Oxytrol(R). In addition, Watson markets the following brands under co-promotion agreements: AndroGel(R), with Solvay Pharmaceuticals, Inc.; and Femring(R), with Warner Chilcott Limited. The Watson pipeline portfolio includes a number of products, including a six-month formulation of TRELSTAR(R), for the treatment of advanced prostate cancer which is currently under review by the FDA; URACYST(R), under development for cystitis; and a novel new oral contraceptive.

For press releases and other company information, visit the Watson website at

Forward-Looking Statement

Any statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Watson's current perspective of existing trends and information as of the date of this release. Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements. Actual results may differ materially from Watson's current expectations depending upon a number of factors affecting Watson's business. These factors include, among others, the impact of competitive products and pricing; market acceptance of and continued demand for Watson's products, including GELNIQUE and RAPAFLO; difficulties or delays in manufacturing; the difficulty of predicting the timing or outcome of FDA or other regulatory agency approvals or actions, if any; patents and other intellectual property rights held by the Company and the ability to successfully enforce such rights against third parties; and other risks and uncertainties detailed in Watson's periodic public filings with the Securities and Exchange Commission, including but not limited to Watson's Annual Report on Form 10-K for the year ended December 31, 2008.


SOURCE Watson Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Companies Continue To Add Wellness Programs, Watson Wyatt/National Business Group On Health Survey Finds
2. Mark G. Watson Named Executive Director of Radiological Society of North America
3. Watson Pharmaceuticals and Elan Settle Lawsuit Over Naproxen Sodium
4. Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results; Provides 2009 Outlook
5. Watson Acknowledges Federal Trade Commission Action Regarding AndroGel Patent Settlement
6. Warner Chilcott and Watson Pharmaceuticals Announce Agreements on Loestrin(R) 24 and Femcon(R) Fe Patent Litigation
7. Watson Pharmaceuticals Receives FDA Approval for Mint Coated Nicotine Gum
8. Watson Pharmaceuticals Receives FDA Final Approval for Generic Mircette(R)
9. U.S. Workers Taking Steps to Lower Medical Costs, Watson Wyatt Survey Finds
10. China Shenghuo Announces Additional Roll-Out of 12 Ways Cosmetics Products to Watsons Stores
11. Driving Consumer Engagement Is Focus of Address by Healthfitness Chief Medical Officer at Watson Wyatt Health Care Solutions Event
Post Your Comments:
(Date:11/26/2015)... Omaha, NE (PRWEB) , ... November 26, 2015 , ... ... careers searched by healthcare professionals and offered by healthcare staffing agency Aureus Medical ... top during the month of October 2015 among those searching for healthcare jobs through ...
(Date:11/26/2015)... CA (PRWEB) , ... November 26, 2015 , ... ... a new set of retro-fused, self-animating trailer titles with ProTrailer: Vintage. This newly ... options. These classically-influenced trailer titles work with any font, giving users limitless opportunities ...
(Date:11/25/2015)... ... 25, 2015 , ... Additional breast cancers found with MRI ... to a study published online in the journal Radiology. Researchers said that in ... a change in treatment. , Breast MRI is the most sensitive technique for ...
(Date:11/25/2015)... ... November 25, 2015 , ... Finnleo, a leader in the traditional and far-infrared ... traditional and far-infrared saunas. , For traditional saunas, Finnleo is offering ... sauna wood, and Finnleo uses only European Grade A Nordic White Spruce from sustainably ...
(Date:11/25/2015)... ... 2015 , ... Dr. John Pierce, Medical Director at the Ageless Forever clinic ... the Capillus272™ Pro laser therapy cap. FDA cleared for safety and efficacy, the Capillus272 ... need for surgery, prescription pills, or topical foams. , “Capillus272™ Pro is a ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... Nov. 26, 2015  The total global healthcare industry is ... 2015-2016. Latin America has the highest ... (excluding Japan ), is second with growth ... to face increased healthcare expenditure. In 2013-2014, total government funded ... 43.5% in 2008-2009 to 41.2% in 2013-2014. In real terms, ...
(Date:11/25/2015)... Nov. 25, 2015  The American Academy of ... (ACOG), and the March of Dimes cheered today,s ... Our Infants Act of 2015 (S.799), which ... newborns born exposed to drugs, such as opioids, ... introduction, all three organizations have worked together leading ...
(Date:11/25/2015)... Nov. 25, 2015 AAIPharma Services Corp./Cambridge ... of at least $15.8  Million to expand its ... NC . The expansion will provide additional ... the growing demands of the pharmaceutical and biotechnology ... expansion will provide up to 40,000 square feet ...
Breaking Medicine Technology: